What is the address of SOLUTION MEDICALE?

The registered office of SOLUTION MEDICALE is located at Rue de la Passerelle(TAM) 12, 5060 Sambreville.

Is SOLUTION MEDICALE still active?

Yes. According to the CBE (17 September 2026) SOLUTION MEDICALE is active, legal situation “Normale toestand”, started on 14 January 2021.

Is SOLUTION MEDICALE registered on Peppol?

No, SOLUTION MEDICALE is currently not registered on the Peppol network.

What is the enterprise number of SOLUTION MEDICALE?

The enterprise number of SOLUTION MEDICALE is BE0761626479.

When was SOLUTION MEDICALE founded?

SOLUTION MEDICALE was founded on 14 January 2021.

Who are the directors of SOLUTION MEDICALE?

According to the 2024 annual accounts, the directors of SOLUTION MEDICALE are: Benoit BIBBO.

Is SOLUTION MEDICALE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 January 2021; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did SOLUTION MEDICALE make in 2024?

SOLUTION MEDICALE posted a profit after taxes of € 5,088 in financial year 2024.

What is the revenue of SOLUTION MEDICALE?

In its most recent annual accounts (2024), SOLUTION MEDICALE reported revenue of € 12,979.

SOLUTION MEDICALE (Private Limited) - Sambreville

Dossier SOLUTION MEDICALE, printed on 17 September 2026 from databakkes.be/en/0761626479/solution-medicale. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2024

SOLUTION MEDICALE from Sambreville, company number BE0761626479, closed financial year 2024 with a result of € 5,088 after tax. For that financial year SOLUTION MEDICALE recorded revenue of € 12,979 and equity of € 14,267. Compared with financial year 2023, the result moved from € 6,870 to € 5,088. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on December 26, 2025.

What it is worth Growing

€ 14,267

▲ 55% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 5,088

▼ 26% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 538

▼ 91% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 12,267.

People and assets in 2024

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 2,974

▼ 46% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	-	-	€ 13,620 Revenue 2023: € 13,620 First fiscal year in the series	€ 12,979 Revenue 2024: € 12,979 ▼ 5% vs 2023 (€ 13,620) Unfavourable step	▼ 5%
Gross margin	€ 12,843 Gross margin 2021: € 12,843 First fiscal year in the series	€ 19,066 Gross margin 2022: € 19,066 ▲ 48% vs 2021 (€ 12,843) Favourable step	€ 7,967 Gross margin 2023: € 7,967 ▼ 58% vs 2022 (€ 19,066) Unfavourable step	€ 7,895 Gross margin 2024: € 7,895 ▼ 1% vs 2023 (€ 7,967) Unfavourable step	▼ 1%
Profit after taxes	€ 9,336 Profit after taxes 2021: € 9,336 First fiscal year in the series	€ 13,972 Profit after taxes 2022: € 13,972 ▲ 50% vs 2021 (€ 9,336) Favourable step	€ 6,870 Profit after taxes 2023: € 6,870 ▼ 51% vs 2022 (€ 13,972) Unfavourable step	€ 5,088 Profit after taxes 2024: € 5,088 ▼ 26% vs 2023 (€ 6,870) Unfavourable step	▼ 26%
Equity	€ 11,336 Equity 2021: € 11,336 First fiscal year in the series	€ 25,309 Equity 2022: € 25,309 ▲ 123% vs 2021 (€ 11,336) Favourable step	€ 9,179 Equity 2023: € 9,179 ▼ 64% vs 2022 (€ 25,309) Unfavourable step	€ 14,267 Equity 2024: € 14,267 ▲ 55% vs 2023 (€ 9,179) Favourable step	▲ 55%
Total debts	€ 32,198 Total debts 2021: € 32,198 First fiscal year in the series	€ 18,050 Total debts 2022: € 18,050 ▼ 44% vs 2021 (€ 32,198) Favourable step	€ 8,525 Total debts 2023: € 8,525 ▼ 53% vs 2022 (€ 18,050) Favourable step	€ 46,254 Total debts 2024: € 46,254 ▲ € 37,730 vs 2023 (€ 8,525) Unfavourable step	▲ € 37,730
Cash	€ 2,110 Cash 2021: € 2,110 First fiscal year in the series	€ 128 Cash 2022: € 128 ▼ 94% vs 2021 (€ 2,110) Unfavourable step	€ 5,700 Cash 2023: € 5,700 ▲ € 5,572 vs 2022 (€ 128) Favourable step	€ 538 Cash 2024: € 538 ▼ 91% vs 2023 (€ 5,700) Unfavourable step	▼ 91%
Retained profit	€ 9,336 Retained profit 2021: € 9,336 First fiscal year in the series	€ 23,309 Retained profit 2022: € 23,309 ▲ 150% vs 2021 (€ 9,336) Favourable step	€ 7,179 Retained profit 2023: € 7,179 ▼ 69% vs 2022 (€ 23,309) Unfavourable step	€ 12,267 Retained profit 2024: € 12,267 ▲ 71% vs 2023 (€ 7,179) Favourable step	▲ 71%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 0 Dividend 2022: € 0 Unchanged (€ 0) Unchanged	€ 23,000 Dividend 2023: € 23,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 23,000) Unchanged	▼ 100%
Balance sheet total	€ 43,534 Balance sheet total 2021: € 43,534 First fiscal year in the series	€ 43,358 Balance sheet total 2022: € 43,358 Unchanged (€ 43,534) Unchanged	€ 17,704 Balance sheet total 2023: € 17,704 ▼ 59% vs 2022 (€ 43,358) Unchanged	€ 60,521 Balance sheet total 2024: € 60,521 ▲ 242% vs 2023 (€ 17,704) Unchanged	▲ 242%

Key figures of SOLUTION MEDICALE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to SOLUTION MEDICALE?

What happened at SOLUTION MEDICALE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 26, 2025 New annual accounts for financial year 2024: profit of € 5,088 (▼ 26% vs 2023). filed late Source: NBB ↗
2023 Benoit BIBBO became a director. NBB
Jan 14, 2021 Start of the company according to the CBE. KBO

In short

From € 9,336 profit in 2021 to € 5,088 profit in 2024.

Paid € 10,126 in corporate taxes since 2021.

Best year ever: 2022, with € 13,972 profit.

Paid out € 23,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at SOLUTION MEDICALE? We notify you, reason included.

Follow SOLUTION MEDICALE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit